Delivering healthy bacteria in a pill could help patients harboring out-of-balance microbial communities.
A Boston startup wants to create precise genome-editing treatments that can address more types of disease than previous gene therapy methods.
A Kansas City hospital is pioneering genomic testing to solve life-threatening mysteries involving infants and kids with developmental disorders.
Genomic technology could accelerate patient trials of new cancer drugs that are targeted to a tumor’s individual molecular profile.
A method for single-cell DNA analysis could provide a safer genetic screen for IVF.
Computer-controlled sedation could lighten the load for intensive-care staff and make the process safer for patients.
A startup will sift through “treasure troves” of data from failed trials to find abandoned Alzheimer’s drugs that might work for some patients.
The U.K. plans to sequence 100,000 National Health Service patients by 2017—in a bold push to be a genomic medicine leader.
The newest cancer drugs cost over $100,000 for a year of treatment. There are fairer ways to set prices.
Today’s medicines can cost hundreds of thousands of dollars a year. The story of how two companies set prices for their costly new drugs suggests that the way we determine the value of such treatments will help decide the future of our health-care system.